Gilead Sciences (NASDAQ:GILD) is set to post its quarterly earnings results after the market closes on Thursday, October 24th. Analysts expect Gilead Sciences to post earnings of $1.66 per share for the quarter. Gilead Sciences has set its FY 2019 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. Gilead Sciences’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.91 EPS. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Gilead Sciences stock opened at $65.86 on Wednesday. The firm has a market capitalization of $83.41 billion, a PE ratio of 10.71, a P/E/G ratio of 2.94 and a beta of 1.10. The company’s 50-day moving average is $64.47 and its 200-day moving average is $65.35. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $72.90. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67.
Several research analysts have recently weighed in on the stock. Morgan Stanley set a $82.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Monday, July 15th. Mizuho set a $81.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Jefferies Financial Group set a $95.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective on the stock in a research note on Monday, July 29th. Finally, Maxim Group set a $84.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $81.36.
In related news, Director Olsen Per Wold sold 4,908 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total value of $313,670.28. Following the transaction, the director now owns 102,762 shares in the company, valued at approximately $6,567,519.42. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the transaction, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: The role of implied volatility with call option volume
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.